I agree with you to a point groins.
However...
Real company news is what matters and being on the N (where biotech's are understood and appreciated) when great things get announced is going to be better than sitting only on the ASX (where as we all know biotechs are very under appreciated).
I believe that as more and more good company news flows as well as trial data, the more US based articles will start to pay attention and report and that raises investor awareness in general in the US and the world. All these factors are going to help not hinder Prima Biomed, patients ultimately but also us investors.
last oppurtunity, page-15
-
- There are more pages in this discussion • 115 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
-0.005(1.45%) |
Mkt cap ! $493.8M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.0¢ | 32.5¢ | $1.317M | 3.935M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73996 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 836970 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |